Published date: 3 April 2024

This notice was replaced on 3 April 2024

This notice does not contain the most up-to-date information about this procurement. The most recent notice is:

Early engagement (published 3 April 2024, last edited 4 April 2024)

Closed early engagement


Contract summary

Industry

  • Pharmaceutical products - 33600000

  • Medicinal products for the respiratory system - 33670000

Location of contract

SW1H 0EU

Procurement reference

CF-2282100D0O000000rwimUAA

Published date

3 April 2024

Closing date

19 April 2024

Contract type

Supply contract

Contract is suitable for SMEs?

Yes

Contract is suitable for VCSEs?

No

Description

DHSC is conducting a market engagement exercise to understand more about the companies and services in the UK that can, or that are seeking to produce, distribute, supply and store different formulations of naloxone and of other drugs that can reverse the effect of an opioid overdose or of drugs taken with opioids.

The outcome of the market engagement will inform decisions around potential future procurement and storage of buffer stock as well as providing information on how the market could meet a potential increase in demand across the UK.

For avoidance of doubt
this is not a call for competition,
the purpose is to seek feedback from the market that may inform the final specification and/or procurement approach to the goods and services.

More information

Attachments

About the buyer

Contact name

Darrell Griffith

Address

39 Victoria Street
London
SW1H 0EU
England

Email

ccsinbox@dhsc.gov.uk